Alumis logo
Alumis
ALMS | NASDAQ
Chart Builder DCF Calculator
$5.14
-$0.46 (-8.21%)
At close: Nov 16, 2026, 4:00 PM ET
$5.05
-$0.09 (-1.75%)
After-hours: Nov 16, 2026, 7:57 PM ET

Alumis Company Profile

Company profile explained

Company Profile

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.

Key Executives

Name Position
Martin Babler President, Chief Executive Officer & Chairman
John R. Schroer Chief Financial Officer
Sanam Pangali Chief Legal Officer & Corporate Secretary
Claire Langrish Senior Vice President & Head of Immunology and Translational Science
David Goldstein Chief Scientific Officer
Jorn Drappa Chief Medical Officer & Head of Research and Development
Kolbot By Senior Vice President & Head of Technical Operations
Mark Bradley Chief Development Officer
Philip Nunn Senior Vice President of Pharmacology & Project Team Leader
Roy C. Hardiman Chief Business & Strategy Officer

Latest SEC Filings

Date Type Title
Sep 09, 2026 4 Filing
Sep 01, 2026 8-K Current Report
Aug 17, 2026 SC 13D Filing
Aug 13, 2026 10-Q Quarterly Report
Aug 13, 2026 8-K Current Report
Aug 10, 2026 8-K Current Report
Aug 06, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 05, 2026 4 Filing
Aug 05, 2026 4 Filing
Aug 05, 2026 4 Filing
View All SEC Filings ➞
Alumis
Alumis logo
Country United States
IPO Date Jun 28, 2024
Industry Biotechnology
Sector Healthcare
Employees 237
CEO Martin Babler

Contact Details

280 East Grand Avenue South San Francisco, California 94080 United States

Stock Details

Ticker Symbol ALMS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001847367
CUSIP Number 022307102
ISIN Number US0223071020
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.